{"transactions":[{"id":305531,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:39:35.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on 03/01/2029."}],"balance_after":11624,"source":{"system":"sec-edgar","filing":"0000875320-26-000267","document":"wk-form4_1788295172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000267/wk-form4_1788295172.xml","form_type":"4"}},{"id":312418,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-02T21:10:00.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":357,"price":483.36,"value":172559.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":6624,"source":{"system":"sec-edgar","filing":"0000875320-26-000125","document":"wk-form4_1772485797.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000125/wk-form4_1772485797.xml","form_type":"4"}},{"id":312739,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-26T22:56:21.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":223,"price":486.35,"value":108456.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":6981,"source":{"system":"sec-edgar","filing":"0000875320-26-000104","document":"wk-form4_1772146579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000104/wk-form4_1772146579.xml","form_type":"4"}},{"id":312738,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-26T22:56:21.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":546,"price":485.11,"value":264870.06,"ownership":{"direct":true},"balance_after":7204,"source":{"system":"sec-edgar","filing":"0000875320-26-000104","document":"wk-form4_1772146579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000104/wk-form4_1772146579.xml","form_type":"4"}},{"id":313157,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:03:25.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":638,"price":473.68,"value":302207.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0000875320-26-000080","document":"wk-form4_1771535003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000080/wk-form4_1771535003.xml","form_type":"4"}},{"id":313156,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:03:25.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":1557,"price":489.46,"value":762089.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":8388,"source":{"system":"sec-edgar","filing":"0000875320-26-000080","document":"wk-form4_1771535003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000080/wk-form4_1771535003.xml","form_type":"4"}},{"id":313155,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:03:25.000Z","date":"2026-02-17","kind":"tax_withholding","planned":true,"acquired":false,"shares":598,"price":483.75,"value":289282.5,"ownership":{"direct":true},"balance_after":9945,"source":{"system":"sec-edgar","filing":"0000875320-26-000080","document":"wk-form4_1771535003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000080/wk-form4_1771535003.xml","form_type":"4"}},{"id":313154,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:03:25.000Z","date":"2026-02-17","kind":"grant","planned":true,"acquired":true,"shares":1809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on February 20, 2027."}],"balance_after":10543,"source":{"system":"sec-edgar","filing":"0000875320-26-000080","document":"wk-form4_1771535003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000080/wk-form4_1771535003.xml","form_type":"4"}},{"id":313482,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:17:47.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1393,"price":487.76,"value":679449.68,"ownership":{"direct":true},"balance_after":8734,"source":{"system":"sec-edgar","filing":"0000875320-26-000058","document":"wk-form4_1771449464.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000058/wk-form4_1771449464.xml","form_type":"4"}},{"id":313871,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:47:43.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":1376,"price":460.43,"value":633551.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":10127,"source":{"system":"sec-edgar","filing":"0000875320-26-000036","document":"wk-form4_1770932861.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000036/wk-form4_1770932861.xml","form_type":"4"}},{"id":313870,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:47:43.000Z","date":"2026-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":592,"price":468.41,"value":277298.72,"ownership":{"direct":true},"balance_after":11503,"source":{"system":"sec-edgar","filing":"0000875320-26-000036","document":"wk-form4_1770932861.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000036/wk-form4_1770932861.xml","form_type":"4"}},{"id":314817,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:12:47.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026."}],"balance_after":12095,"source":{"system":"sec-edgar","filing":"0001856587-26-000002","document":"wk-form4_1769461964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000185658726000002/wk-form4_1769461964.xml","form_type":"4"}},{"id":314816,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:12:47.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026."}],"balance_after":10795,"source":{"system":"sec-edgar","filing":"0001856587-26-000002","document":"wk-form4_1769461964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000185658726000002/wk-form4_1769461964.xml","form_type":"4"}},{"id":325026,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T21:24:54.000Z","date":"2025-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":1241,"price":479.61,"value":595196.01,"ownership":{"direct":true},"balance_after":7845,"source":{"system":"sec-edgar","filing":"0000875320-25-000122","document":"wk-form4_1740777887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000122/wk-form4_1740777887.xml","form_type":"4"}},{"id":325183,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-26T21:06:23.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":884,"price":480.95,"value":425159.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024."}],"balance_after":9086,"source":{"system":"sec-edgar","filing":"0000875320-25-000103","document":"wk-form4_1740603976.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000103/wk-form4_1740603976.xml","form_type":"4"}},{"id":325182,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-26T21:06:23.000Z","date":"2025-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":828,"price":483.28,"value":400155.84,"ownership":{"direct":true},"balance_after":9970,"source":{"system":"sec-edgar","filing":"0000875320-25-000103","document":"wk-form4_1740603976.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000103/wk-form4_1740603976.xml","form_type":"4"}},{"id":325790,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:21:31.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":671,"price":455.06,"value":305345.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024."}],"balance_after":10798,"source":{"system":"sec-edgar","filing":"0000875320-25-000079","document":"wk-form4_1740000082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000079/wk-form4_1740000082.xml","form_type":"4"}},{"id":325789,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:21:31.000Z","date":"2025-02-14","kind":"tax_withholding","planned":true,"acquired":false,"shares":564,"price":463.46,"value":261391.44,"ownership":{"direct":true},"balance_after":11469,"source":{"system":"sec-edgar","filing":"0000875320-25-000079","document":"wk-form4_1740000082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000079/wk-form4_1740000082.xml","form_type":"4"}},{"id":326073,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:04:49.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":2080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":12033,"source":{"system":"sec-edgar","filing":"0000875320-25-000057","document":"wk-form4_1739567081.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000057/wk-form4_1739567081.xml","form_type":"4"}},{"id":326177,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-12T21:24:10.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":1376,"price":459.83,"value":632726.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms.  Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024."}],"balance_after":9953,"source":{"system":"sec-edgar","filing":"0000875320-25-000033","document":"wk-form4_1739395442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000033/wk-form4_1739395442.xml","form_type":"4"}},{"id":326176,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-12T21:24:10.000Z","date":"2025-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":591,"price":467.98,"value":276576.18,"ownership":{"direct":true},"balance_after":11329,"source":{"system":"sec-edgar","filing":"0000875320-25-000033","document":"wk-form4_1739395442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000033/wk-form4_1739395442.xml","form_type":"4"}},{"id":326561,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:31.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":1854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":11920,"source":{"system":"sec-edgar","filing":"0000875320-25-000007","document":"wk-form4_1738876523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000007/wk-form4_1738876523.xml","form_type":"4"}},{"id":326560,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:31.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025."}],"balance_after":10066,"source":{"system":"sec-edgar","filing":"0000875320-25-000007","document":"wk-form4_1738876523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000007/wk-form4_1738876523.xml","form_type":"4"}},{"id":335834,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-04-03T20:02:22.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":240,"price":419,"value":100560.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0000875320-24-000113","document":"wk-form4_1712174533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000113/wk-form4_1712174533.xml","form_type":"4"}},{"id":335833,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-04-03T20:02:22.000Z","date":"2024-04-01","kind":"tax_withholding","planned":true,"acquired":false,"shares":225,"price":418.1,"value":94072.5,"ownership":{"direct":true},"balance_after":7740,"source":{"system":"sec-edgar","filing":"0000875320-24-000113","document":"wk-form4_1712174533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000113/wk-form4_1712174533.xml","form_type":"4"}},{"id":339129,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-27T21:29:19.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":883,"price":425.7,"value":375893.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":7965,"source":{"system":"sec-edgar","filing":"0000875320-24-000097","document":"wk-form4_1709069345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000097/wk-form4_1709069345.xml","form_type":"4"}},{"id":339128,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-27T21:29:19.000Z","date":"2024-02-23","kind":"tax_withholding","planned":true,"acquired":false,"shares":828,"price":431.79,"value":357522.12,"ownership":{"direct":true},"balance_after":8848,"source":{"system":"sec-edgar","filing":"0000875320-24-000097","document":"wk-form4_1709069345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000097/wk-form4_1709069345.xml","form_type":"4"}},{"id":340506,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-13T21:48:51.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":1374,"price":420.24,"value":577409.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms.Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":9676,"source":{"system":"sec-edgar","filing":"0000875320-24-000041","document":"wk-form4_1707860917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000041/wk-form4_1707860917.xml","form_type":"4"}},{"id":340505,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-13T21:48:51.000Z","date":"2024-02-09","kind":"tax_withholding","planned":true,"acquired":false,"shares":591,"price":422.74,"value":249839.34,"ownership":{"direct":true},"balance_after":11050,"source":{"system":"sec-edgar","filing":"0000875320-24-000041","document":"wk-form4_1707860917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000041/wk-form4_1707860917.xml","form_type":"4"}},{"id":341087,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-08T21:20:39.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":1853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":11641,"source":{"system":"sec-edgar","filing":"0000875320-24-000016","document":"wk-form4_1707427226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000016/wk-form4_1707427226.xml","form_type":"4"}},{"id":341086,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-08T21:20:39.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":9788,"source":{"system":"sec-edgar","filing":"0000875320-24-000016","document":"wk-form4_1707427226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000016/wk-form4_1707427226.xml","form_type":"4"}},{"id":348592,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-06-01T20:12:55.000Z","date":"2023-05-30","kind":"sale","planned":true,"acquired":false,"shares":289,"price":329.82,"value":95317.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":6838,"source":{"system":"sec-edgar","filing":"0001209191-23-033312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123033312/doc4.xml","form_type":"4"}},{"id":350479,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-04-04T20:18:15.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":176,"price":313.74,"value":55218.24,"ownership":{"direct":true},"balance_after":7127,"source":{"system":"sec-edgar","filing":"0001209191-23-022689","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123022689/doc4.xml","form_type":"4"}},{"id":352338,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-28T21:44:44.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":42,"price":289.63,"value":12164.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."}],"balance_after":7303,"source":{"system":"sec-edgar","filing":"0001209191-23-013695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013695/doc4.xml","form_type":"4"}},{"id":352337,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-28T21:44:44.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":183,"price":288.68,"value":52828.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $288.68 (range $288.24 to $289.17)."}],"balance_after":7345,"source":{"system":"sec-edgar","filing":"0001209191-23-013695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013695/doc4.xml","form_type":"4"}},{"id":352336,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-28T21:44:44.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":982,"price":287.25,"value":282079.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $287.25 (range $286.79 to $287.71)."}],"balance_after":7528,"source":{"system":"sec-edgar","filing":"0001209191-23-013695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013695/doc4.xml","form_type":"4"}},{"id":352335,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-28T21:44:44.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":502,"price":289.12,"value":145138.24,"ownership":{"direct":true},"balance_after":8510,"source":{"system":"sec-edgar","filing":"0001209191-23-013695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013695/doc4.xml","form_type":"4"}},{"id":354164,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-03T21:32:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":9012,"source":{"system":"sec-edgar","filing":"0001209191-23-006879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006879/doc4.xml","form_type":"4"}},{"id":354163,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-03T21:32:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023."}],"balance_after":6062,"source":{"system":"sec-edgar","filing":"0001209191-23-006879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006879/doc4.xml","form_type":"4"}},{"id":362189,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-27T20:05:27.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":104,"price":271.68,"value":28254.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $271.68 (range $271.25 to $272.23)."}],"balance_after":3496,"source":{"system":"sec-edgar","filing":"0000899243-22-015762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322015762/doc4.xml","form_type":"4"}},{"id":362188,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-27T20:05:27.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":83,"price":269.51,"value":22369.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $269.51 (range $269.12 to $269.90)."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0000899243-22-015762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322015762/doc4.xml","form_type":"4"}},{"id":362187,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-27T20:05:27.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":80,"price":268.46,"value":21476.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $268.46 (range $268.05 to $268.86)."}],"balance_after":3683,"source":{"system":"sec-edgar","filing":"0000899243-22-015762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322015762/doc4.xml","form_type":"4"}},{"id":362186,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-27T20:05:27.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":60,"price":267.37,"value":16042.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $267.37 (range $266.86 to $267.85)."}],"balance_after":3763,"source":{"system":"sec-edgar","filing":"0000899243-22-015762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322015762/doc4.xml","form_type":"4"}},{"id":363060,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-05T20:06:19.000Z","date":"2022-04-01","kind":"tax_withholding","acquired":false,"shares":137,"price":263.09,"value":36043.33,"ownership":{"direct":true},"balance_after":3823,"source":{"system":"sec-edgar","filing":"0000899243-22-013713","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322013713/doc4.xml","form_type":"4"}},{"id":366679,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-02-03T21:09:33.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2023."}],"balance_after":3960,"source":{"system":"sec-edgar","filing":"0001209191-22-006761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006761/doc4.xml","form_type":"4"}}]}